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Abstract
About 50% of patients with breast cancer have no involvement
of axillary lymph nodes at diagnosis and can be considered
cured after primary locoregional treatment. However, about 20–
30% will experience distant relapse. The group of patients at
risk is not well characterised: recurrence is probably due to the
establishment of micrometastases before treatment. Given the
early steps of metastasis in which tumour cells interact with
endothelial cells of blood vessels, and, given the independent
prognostic value in breast cancer of both the quantification of
tumour vascularisation and the detection of micrometastases in
the bone marrow, the aim of this study was to determine the
relationship between vascularisation, measured by Chalkley
morphometry, and the bone marrow content of cytokeratin-19
(CK-19) mRNA, quantified by real-time reverse transcriptase
polymerase chain reaction, in a series of 68 patients with
localised untreated breast cancer. The blood concentration of
factors involved in angiogenesis (interleukin-6 and vascular
endothelial growth factor) and of factors involved in coagulation
(D-dimer, fibrinogen, platelets) was also measured. When bone
marrow CK-19 relative gene expression (RGE) was categorised
according to the cut-off value of 0.77 (95th centile of control
patients), 53% of the patients had an elevated CK-19 RGE.
Patients with bone marrow micrometastases, on the basis of an
elevated CK-19 RGE, had a mean Chalkley count of 7.5 ± 1.7
(median 7, standard error [SE] 0.30) compared with a mean
Chalkley count of 6.5 ± 1.7 in other patients (median 6, SE 0.3)
(Mann–Whitney U-test; P = 0.04). Multiple regression analysis
revealed that Chalkley count, not lymph node status,
independently predicted CK-19 RGE status (P = 0.04; odds
ratio 1.38; 95% confidence interval 1.009–1.882). Blood
parameters reflecting angiogenesis and coagulation were
positively correlated with Chalkley count and/or CK-19 RGE.
Our data are in support of an association between elevated
relative microvessel area of the primary tumour and the presence
of bone marrow micrometastases in breast cancer patients with
operable disease, and corroborate the paracrine and endocrine
role of interleukin-6 and the involvement of coagulation in breast
cancer growth and metastasis.
Keywords: angiogenesis, bone marrow, breast cancer, Chalkley, micrometastasis.
Introduction
The development of distant metastases is the primary
cause of death in breast cancer patients. The involvement
of the axillary lymph nodes, tumour size, histopathological
grade and hormone receptor status determine prognosis
and treatment options at initial diagnosis [1]. Nevertheless,
these parameters do not accurately predict which patients
CK = cytokeratin; ELISA = enzyme-linked immunosorbent assay; IL = interleukin; RGE = relative gene expression; RT–PCR = reverse transcriptase 
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will relapse after primary treatment, and they give limited
information about the effectiveness of adjuvant treatment.
About 50% of patients have no involvement of the axillary
lymph nodes at diagnosis and can therefore be considered
cured after primary locoregional treatment. However, about
20–30% will experience distant relapse within 5–10 years,
suggesting outgrowth of disseminated tumour cells
present at diagnosis and undetectable by the current diag-
nostics [2]. This prompted the refinement of methods able
to detect subclinical tumour deposits in various body
compartments.
Tumour cells residing in bone marrow are considered to
mirror the efficacy of the metastatic process throughout the
body. Several prospectively designed clinical trials have
confirmed the independent prognostic significance of the
lodging of tumour cells in the bone marrow [3], suggesting
that this minimal disease is indeed the progenitor of mani-
fest metastasis. It is not clear whether the tumour cells that
are part of subclinical metastases have arisen early during
progression of the primary tumour or whether they are late
and rare metastatic variants as a result of the cumulative
acquisition of malignant phenotypic traits such as self-suf-
ficiency in growth signals, insensitivity to anti-growth sig-
nals, evasion of apoptosis, limitless replicative potential,
genomic instability, tissue invasion and sustained angio-
genesis [4-6].
Bone marrow micrometastasis can be detected by immu-
nocytochemical analyses with antibodies directed at epi-
thelial markers. Polymerase chain reaction (PCR)-based
techniques that amplify epithelial mRNA are more sensitive
but need the introduction of cut-off values for positivity to
correct for the inevitable loss of specificity.
The concept of dependence on vascularisation of growth,
invasion and metastasis of malignant tumours has been
challenged by the description of angiogenesis-independ-
ent mechanisms [7-10]. Nevertheless, the growth of most
primary tumours needs angiogenesis. There is accumulat-
ing evidence that angiogenesis is intrinsically linked with
the process of haemostasis [11]. Both angiogenesis and
haemostasis are tightly regulated in physiological circum-
stances, for example during wound healing, but are dereg-
ulated when involved in tumour growth, invasion and
metastasis. We have previously demonstrated the prog-
nostic importance of the angiogenic cytokine interleukin
(IL)-6, and the fibrin degradation product D-dimer, in
patients with metastatic breast cancer [12,13].
A reproducible method of quantifying vascularisation, by
assessing the relative microvessel area, is Chalkley point
overlap morphometry [14]. Significant associations
between the Chalkley count and axillary lymph node metas-
tasis, increasing tumour size, high grade and histological
subtype have been reported in patients with breast cancer.
Moreover, an independent prognostic value has been dem-
onstrated in patients with breast cancer by a meta-analysis
of 87 published studies [15]. Chalkley counting is done in
selected areas of high microvessel density, so-called 'hot
spots'. The hypothetical rationale for counting in these
highly vascular areas is that they predict the presence of
more angiogenic subclones of the tumour [16]. These sub-
clones might therefore have a higher metastatic efficiency.
The primary aim of this study was to assess the association
of tumour vascularity, quantified by a well-standardised
morphometrical method, and the presence of bone marrow
micrometastases, detected by a sensitive and quantitative
real-time reverse transcriptase PCR (RT–PCR) technique,
in patients with operable breast cancer before treatment, to
evaluate the relative microvessel area as a surrogate marker
of bone marrow micrometastasis, as suggested by Fox and
colleagues [17].
Materials and methods
Patients
Blood and bone marrow samples were collected preoper-
atively in 68 consecutive patients with localised, untreated,
operable breast cancer. Eleven patients with a haematolog-
ical malignancy who underwent bone marrow sampling for
diagnostic purposes were entered as control patients for
cytokeratin-19 (CK-19) relative gene expression (RGE).
Tissue
A representative, full cross-section of the tumour sample
surrounded by adjacent normal breast tissue was taken
from all tumours. The tissue was fixed in buffered formalin
and was paraffin-embedded. Sections 5 µm thick were cut
and mounted on poly-L-lysine-coated slides.
Blood coagulation tests
Plasma collection and measurement of fibrinogen, platelet
counts and D-dimer levels were performed as described
previously [12].
Chalkley morphometry
Tumour vascularisation was evaluated by the Chalkley
method, a morphometric point overlap counting system
using a microscope eyepiece graticule. It has been shown
to be both a rapid and a reproducible method that gives
independent prognostic information and has been sug-
gested as a standard method in an international consensus
report on the quantification of angiogenesis [14]. In brief, a
representative paraffin section including the tumour border
was immunostained with a monoclonal anti-CD34 antibody
(clone QBEnd/10; Biogenex, San Ramon, CA, USA)
diluted 1:5 with overnight incubation at 4°C and without
antigen retrieval procedure. The areas of highest vascularAvailable online http://breast-cancer-research.com/content/7/2/R210
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density ('hot spots') were identified at low magnification (×
10 ocular and × 10 objective). On a higher magnification (×
10 ocular and × 20 objective), a 25-point Chalkley eye-
piece graticule (Chalkley grid area 0.22 mm2) was applied
to each hot spot and orientated to permit the maximum
number of points to hit on or in a microvessel. The Chalkley
count in the hot spot with highest vascular density (the larg-
est number of hits) was used for further analyses.
Enzyme-linked immunosorbent assay (ELISA) of 
angiogenic cytokines
Serum samples were collected in serum separator tubes
(type Vacutainer; Becton-Dickinson) and centrifuged at
2000  g  for 5 min. Measurements of serum vascular
endothelial growth factor (VEGF)-A165 and IL-6 were per-
formed as described previously [18]. Plasma (Becton-Dick-
inson Vacutainer tubes type 9NC 0.129 M, 4.5 ml) VEGF-
A165 was measured with an ELISA kit (R&D Systems, Min-
neapolis, MN, USA) on trisodium citrate-anticoagulated
collected blood. For the ELISA assay of VEGF-A165, no
cross-reactivity with other VEGF-A isoforms is docu-
mented. No cross-reactivity and no interference was found
with IL-6-related (for example leukaemia inhibitory factor
and oncostatin M) and growth factors not related to IL-6
(for example human platelet-derived growth factor and IL-7)
(Quantikine human IL-6; R&D Systems, Minneapolis, MN,
USA). Samples were assayed in duplicate. Within-assay
variability had been tested before and was limited [18].
Bone marrow sampling
Bone marrow (9 ml) was aspirated from the posterior iliac
crest under local anaesthesia into syringes containing
heparin as anticoagulant (Becton-Dickinson Vacutainer
tubes type NH 170 IU 10 ml). Mononuclear cells were iso-
lated by density-gradient centrifugation through Ficoll-
Paque (Amersham Pharmacia Biotech) and washed twice
with phosphate-buffered saline. After final centrifugation,
the cell pellets were resuspended in a guanidine-containing
buffer and stored at -70°C.
Cell line
The MDA-MB 361 cell line (American Type Culture Collec-
tion [ATCC] catalogue code HTB-27) was cultured in Lei-
bovitz's L-15 medium with a free gas exchange with
atmospheric air, and supplemented with 20% fetal bovine
serum and antibiotics. The medium was replaced every 3–
4 days. Cells were harvested in accordance with the ATCC
guidelines.
RNA isolation and cDNA synthesis
Total RNA was extracted from the mononuclear cell fraction
with the RNeasy kit (Qiagen). The amount of RNA was
measured spectrophotometrically. Only samples with an
A260/A280 ratio of more than 1.8, indicating high purity,
were used. The RNA integrity was tested with the Agilent
Bioanalyzer (Agilent Technologies). Only samples with a
lack of degradation on the electrophoretogram and with a
28S/18S ratio of at least 1.9 were analysed. For first cDNA
strand generation, 2 µg of total RNA was reverse-tran-
scribed with the High-Capacity cDNA Archive kit (Applied
Biosystems) in a total volume of 100 µl.
Primers and probe design
Primers and probe for CK-19 were designed with the aid of
Primer Express software (Applied Biosystems). To avoid
amplification of contaminating genomic DNA, primers and
probe were located on different exons.
The forward primer of CK-19 (5'-CCCGCGACTA-
CAGCCACTA-3') is situated on exon 1, the probe (5'-
Table 1
Clinicopathological characteristics of patients and tumours (N 
= 68)
Characteristic Value
Mean age in years (SD) 60.6 (12.3)
T status
T1 30
T2 15
T3 13
T4 10
N status
N0 36
N1 28
N2 4
Hormone receptor status
ER+ and/or PgR+ 59
ER-/PgR- 9
Tumour differentiation
I2 7
II 27
III 14
Menopausal status
Pre- and perimenopausal 11
Postmenopausal 57
Histology
IDA 59
ILA 8
Medullar 1
ER, oestrogen receptor; IDA, invasive ductal adenocarcinoma; ILA, 
invasive lobular adenocarcinoma; PR, progesteronereceptor; SD, 
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ACCATTGAGAACTCCAGGATTGTCCTGCA-3', labelled
with 6-carboxyfluorescein [FAM] at the 5' end and 6-car-
boxy-tetramethylrhodamine [TAMRA] at the 3' end) on exon
2 and the reverse primer (5'-CTCATGCGCAGAGCCT-
GTT-3') on exon 3. RT-PCR with this primer set resulted in
a 163-base-pair fragment. The nucleotide sequences of the
primers and probe were checked for their specificity in the
NCI BLAST®  database. The amplification product was
sequenced and was comparable with the predicted nucle-
otide sequence.
PCR amplification
All PCR reactions were performed on the ABI Prism 7700
Sequence Detection System (Applied Biosystems) with
the fluorescent Taqman method. Mispriming of processed
pseudogenes was excluded.
The CK-19 mRNA quantities were analysed in triplicate,
normalised against β-actin as a control gene and were
expressed in relation to a calibrator sample. The calibrator
was produced from the blood of a healthy volunteer spiked
with five MDA-MB 361 cells per 106 mononuclear cells.
The calibrator was given a RGE of 100. As described by
Livak and colleagues [19], results are expressed as RGE
with the ∆∆CT method.
Ethical considerations
The Ethical Committee of both institutions approved this
study. Written informed consent was obtained from all
patients.
Statistical analysis
Statistical analysis was performed with Graphpad Prism
(version 2.0; Graphpad Software, Inc.). For IL-6 and VEGF-
A ELISA assays, half of the detection limit value of the
patient samples was used for statistical analysis in case the
measured values did not reach the detection limit of the
assay. Detection limits were 0.7 and 9 pg/ml, respectively.
Comparisons of continuous variables were performed with
the Mann–Whitney U-test. Relationship between
Table 2
Contingency table comparing vascularisation (Chalkley count: low [less than 7] and high [7 or more]) with the clinicopathological 
characteristics of the patients with breast cancer (χ2 test P value)
Characteristic Vascularisation P
Low High
Age in years
<50 4 (40%) 6 (60%) 0.97
50–64 12 (36%) 21 (64%)
>65 9 (36%) 16 (64%)
Lymph node status
Negative 16 (44%) 20 (56%) 0.26
Positive 10 (31%) 22 (69%)
Grade
I 10 (37%) 17 (63%) 0.79
II 9 (33%) 18 (67%)
III 6 (43%) 8 (57%)
Oestrogen receptor
Negative 17 (34%) 33 (66%) 0.43
Positive 8 (44%) 10 (56%)
Micrometastases (CK-19 RGE)
≥ 0.77 10 (30%) 23 (70%) 0.04
<0.77 15 (52%) 14 (48%)
T-stage
T1/T2 21 (47%) 24 (53%) 0.05
T3/T4 5 (22%) 18 (78%)
CK-19 RGE, cytokeratin-19 relative gene expression.Available online http://breast-cancer-research.com/content/7/2/R210
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categorical variables was validated with a χ2 test. The cor-
relation of continuous variables was analysed with a Spear-
man rank test. A multiple regression analysis was
performed with a stepwise-backward likelihood procedure.
P < 0.05 was necessary for statistical significance.
Results
Patients
Age, T status, N status, oestrogen and progesterone
receptor-status, tumour differentiation, menopausal status
and tumour histology are given in Table 1.
CK-19 RGE
Quantification of the mRNA transcripts of CK-19 in the
bone marrow aspirates could be performed in all control
samples and in 62 bone marrow samples of patients with
breast cancer. In six patients, the volume of bone marrow or
the quality of RNA was insufficient. A median RGE of 0.57
(range 0.22–0.78) was found for the control samples.
Patients with primary breast cancer had a mean RGE of
3.85 ± 20.95 (median 0.79, standard error [SE] 2.66). Val-
ues above the 95th centile of the control values (0.77) were
considered to indicate the presence of bone marrow
micrometastasis. With this cut-off, 33 of 62 patients (53%)
had bone marrow micrometastasis. In 49% of patients
there was a concordance between lymph node status and
bone marrow status. Fifty-five percent of patients with bone
marrow micrometastasis had negative lymph nodes. Forty-
six percent of patients without bone marrow micrometasta-
sis had positive lymph nodes. Fifty-five percent of patients
without lymph node metastasis had bone marrow
micrometastasis. Forty-six percent of patients with lymph
node metastasis had no bone marrow micrometastases.
Chalkley count
Quantification of relative microvessel area by Chalkley mor-
phometry was performed in all (n = 68) breast cancer sam-
ples. A mean value of 7.1 ± 1.9 (median 7, SE 0.23) was
found. The median value of 7 was taken as a cut-off for cat-
egorisation into 'high' (7 or more) and 'low' Chalkley count.
There was a positive association of Chalkley count with T-
stage, but not with lymph node status (Table 2).
CK-19 RGE and Chalkley count
Considering both Chalkley counts and CK-19 RGE as con-
tinuous variables, a significant correlation was found (r =
0.26, P = 0.04; Fig. 1a).
Sixty-two percent (23 of 37 patients) of breast tumours
with a high Chalkley count were related to a bone marrow
sample with positive CK-19 RGE. This was true for only
40% (10 of 25 patients) of breast tumours with a low
Chalkley count (χ2 test P = 0.04).
Patients with a CK-19 RGE of 0.77 or more had a tumour
with a mean Chalkley count of 7.5 ± 1.7 (median 7.0, SE
0.3) compared with 6.5 ± 1.7 (median 6.0, SE 0.3) in
patients with a CK-19 RGE of less than 0.77 (Mann–Whit-
ney U-test P = 0.04; Fig. 1b).
A stepwise-backward likelihood multiple regression analy-
sis for the prediction of the presence of bone marrow
micrometastases was performed, including Chalkley count,
serum IL-6, D-dimers, fibrinogen, platelet count, serum
VEGF-A, plasma VEGF-A, T-stage, N-stage, oestrogen
receptor status, progesterone receptor status, tumour type
and differentiation status. Only Chalkley count, as a contin-
Figure 1
Chalkley count and relative gene expression of cytokeratin-19 (CK-19  RGE) Chalkley count and relative gene expression of cytokeratin-19 (CK-19 
RGE). (a) Correlation analysis of Chalkley count and CK-19 RGE. (b) 
Chalkley counts of patients with and without bone marrow metastases 
(according to the cut-off value of 0.77 for CK-19 RGE). Box-and-
whisker plot limits depict 75th and 25th centiles and median value 
(box), and upper/lower quantile ± 1.5 × (interquantile range) (upper 
and lower whiskers, respectively).Breast Cancer Research    Vol 7 No 2    Benoy et al.
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uous variable, independently predicted CK-19 RGE status
(P  = 0.04; odds ratio 1.38; 95% confidence interval
1.009–1.882).
Coagulation parameters and angiogenesis parameters 
in blood
Values and associations are given in Tables 3 and 4. In gen-
eral, parameters reflecting coagulation and angiogenesis in
blood had positive significant associations.
Chalkley count, coagulation parameters and 
angiogenesis parameters in blood
Serum IL-6 levels were correlated with Chalkley count (r =
0.2, P = 0.08; Fig. 2a). The mean IL-6 concentration in the
serum of patients with a high Chalkley count was 2.57 ±
3.75 pg/ml (median 1.10, SE 0.57), and 1.52 ± 4.21 pg/ml
(median 0.35, SE 0.84; Mann–Whitney U-test P = 0.018;
Fig. 2b) in patients with a low Chalkley count. Platelet count
in patients with a high Chalkley count was (282.8 ± 64.6)
× 103/µl (median 272, SE 9.8), and (240 ± 73.9) × 103/µl
(median 243, SE 14.8; Mann–Whitney U-test P = 0.02;
Fig. 3) in patients with a low Chalkley count.
CK-19 RGE, coagulation parameters and angiogenesis 
parameters in blood
D-dimer levels were correlated (r = 0.22, P = 0.08; Fig. 4a)
with CK-19 RGE. Forty-one patients had elevated (more
than 250 ng/ml) D-dimer levels. A mean D-dimer concen-
tration of 477 ± 362 ng/ml (median 319, SE 67) was found
in patients with CK-19 RGE values of less than 0.77,
whereas the mean D-dimer level was 674 ± 634 ng/ml in
patients with a CK-19 RGE value of 0.77 or more (median
458.5, SE 115.8; Mann–Whitney U-test P = 0.09; Fig. 4b).
No associations between CK-19 RGE and other variables
were found (data not shown).
Discussion
The relation between the relative microvessel area, quanti-
fied by Chalkley counting of immunostained blood vessels
in sections of primary breast cancer, and the pre-operative
quantification of micrometastases in bone marrow by Taq-
man real-time RT–PCR was investigated in a group of
patients with primary breast cancer before the start of treat-
ment. Every increase in Chalkley count independently pre-
dicted a higher likelihood of bone marrow epithelial cells
(odds ratio of 1.4) in patients with non-metastatic breast
cancer. Patients with RGE of CK-19 in the bone marrow
Table 3
Coagulation and angiogenesis factors
Factor N Mean (median) SD (SE) 95% CI
sIL-6 68 2.18 (0.35) 3.92 (0.48) 1.21–3.13
sVEGF 68 356.4 (285.9) 259.5 (31.47) 293.5–419.2
pVEGF 67 34.81 (22.2) 52.56 (6.42) 21.99–47.63
D-D 63 570.1 (419) 504.9 (63.61) 442.9–697.2
Platelets 68 267.2 (266) 70.66 (8.57) 250.1–284.3
Fibrinogen 63 320.9 (306) 73.47 (9.26) 302.4–339.4
sVEGF/pl 68 1.37 (1.15) 0.92 (0.11) 1.15–1.60
Abbreviations and units: D-D, D-dimers (ng/ml); platelets, 103 platelets/µl; pVEGF, plasma vascular endothelial growth factor (pg/ml); sIL-6, serum 
interleukin-6 (pg/ml); sVEGF, serum VEGF (pg/ml); sVEGF/pl, serum VEGF (pg/ml) per 106 platelets. Fibrinogen is shown in mg/dl. CI, 
confidence interval; SD, standard deviation; SE, standard error.
Table 4
Correlation of coagulation and angiogenesis markers
r/P
sIL-6 sVEGF pVEGF D-D Platelets Fibrinogen sVEGF/pl
sIL-6 0.25/0.03 0.33/0.005 0.41/0.006 0.23/0.06 0.22/0.06
sVEGF 0.48/<0.001 0.25/0.04 0.22/0.06 0.88/<0.0001
pVEGF 0.38/0.0019 0.23/0.05 0.26/0.0339 0.38/0.001
D-D 0.26/0.03 0.34/0.0061
D-D, D-dimers; pVEGF, plasma vascular endothelial growth factor; sIL-6, serum interleukin-6; sVEGF, serum VEGF; sVEGF/pl, serum VEGF per 
106 platelets. Spearman correlation test r values and P values (r/P) are given if there was a statistical trend or a significant difference.Available online http://breast-cancer-research.com/content/7/2/R210
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above the 95th centile of a control population had a primary
tumour with a Chalkley count of 7.5, compared with 6.5 in
patients without PCR-detected bone marrow micrometas-
tases (P = 0.04).
Our work confirms the study by Fox and colleagues [17]. In
214 patients with primary breast cancer, tumour cells were
detected through the examination of epithelial membrane
antigen expression and the analysis of cell morphology. In
immunostained breast cancer sections, a semi-quantitative
vascular grade, expressed as being low or high, was deter-
mined in so-called vascular hot spots. Absolute concord-
ance by kappa statistics of this vascular grade and Chalkley
count was reported in a small subset of 22 patients. High
vascular grade and the presence of vascular invasion inde-
pendently predicted the presence of bone marrow
micrometastases (respective odds ratios 2.7 and 2.7). In
our study, Chalkley counts were determined in all 68
patients. However, the main difference lies in the higher
sensitivity of Taqman quantitative real-time RT–PCR than
that of immunocytochemistry on bone marrow cytospins
used by Fox and colleagues [17].
This study corroborates the well-documented prognostic
value of the Chalkley count in breast cancer [20]. Hansen
and colleagues [20] categorised Chalkley counts by using
cut-off points of 5 and 7. Patients with Chalkley counts of
7 or more had a hazard ratio for death of 1.46 (95% confi-
dence interval 1.14–1.87) compared with the group of
patients with Chalkley counts between 5 and 7. Bone mar-
row micrometastases are predicted by a high Chalkley
count ([17] and this study) and have been linked to adverse
outcome in patients with breast cancer: currently, about
2500 patients with breast cancer have been analysed in
five prospectively designed clinical trials to verify associa-
tions between the presence of immunostained tumour cells
in bone marrow and prognosis [3]. Braun and colleagues
[21] have included 552 patients with stage I, II and III
breast cancer in a prospective study: the presence of
tumour cells detected with the antibody A45-B/B3 inde-
pendently predicted distant metastasis but not locore-
gional recurrence. The association of a high Chalkley count
with the presence of tumour cells in the bone marrow
explains at least partly the prognostic value of the former
parameter.
The presence or absence of lymph node metastases did
not predict the bone marrow CK-19 RGE status by multiple
regression analysis in this study. Concordance between
bone marrow status and lymph node status was present in
Figure 2
Chalkley count and interleukin-6 (IL-6) Chalkley count and interleukin-6 (IL-6). (a) Correlation of IL-6 serum lev-
els and Chalkley count. (b) IL-6 serum levels of patients with a tumour 
with high and low Chalkley count (according to the cut-off value of 7).
Figure 3
Analysis of platelet count in relation to high and low Chalkley count  (according to the cut-off value of 7) Analysis of platelet count in relation to high and low Chalkley count 
(according to the cut-off value of 7).Breast Cancer Research    Vol 7 No 2    Benoy et al.
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only 49% of all patients. This is in accord with results of
cDNA array analyses of primary breast tumours of bone
marrow-positive and bone marrow-negative patients [22].
Distinct profiles were reported, indicating that bone mar-
row metastasis is a selective process with a specific molec-
ular signature of the primary breast tumour. In addition, in a
prognostic study of patients with operable breast cancer,
the bone marrow status provided independent information
in addition to tumour size and lymph node status in a multi-
variate analysis [23]. The presence of bone marrow
micrometastases was related to earlier recurrence.
Although we did not compare the CK-19 RGE with the
number of immunostained tumour cells in bone marrow
cytospins in this study, the Taqman quantitative real-time
RT–PCR methodology has been validated by us in a group
of patients with metastatic breast cancer [24]. RT–PCR
quantification of mRNA transcripts of epithelial cells has a
high sensitivity but a rather poor specificity for the detection
of tumour cells in bone marrow or blood. The main reason
for this is the expression of some epithelial markers, such
as CK-19, by haematopoietic and blood cells. A stringent
cut-off for CK-19 RGE positivity has therefore been set in
this study. Methodological adaptations to avoid mispriming
due to pseudogenes and to avoid amplification of contam-
inating DNA have also been made. Expression of the CK-
19 RGE as an absolute number of tumour cells was not
performed, because of unpredictable variations of the
expression levels of CK-19 mRNA in tumour cells from indi-
vidual patients.
What are the putative tumour-biological mechanisms to
explain the positive association between the extent of
tumour vascularisation and the amount of disseminated epi-
thelial cells, and thus probably to a large extent 'tumour'
cells, in the bone marrow of breast cancer patients? A first
explanation might be that intravasation of breast cancer
cells, one of the initial steps of metastasis, is facilitated in
tumours with extensive vascularisation [25-27]. McCulloch
and colleagues [28] indeed demonstrated a positive asso-
ciation between, on the one hand, the number of tumour
cells in the blood of the veins draining the breast gland dur-
ing surgery and, on the other, the vascularity of the primary
tumour [28,29]. Although mechanical stress due to diag-
nostic procedures, such as mammography, or due to sur-
gery itself can augment tumour cell shedding, this study
links high vascularity to increased intravasation of breast
cancer cells in a peri-operative setting. A comparable pos-
itive relation between breast tumour vascularity and CK-19
mRNA in the blood was found in patients 2–3 weeks after
surgery [30]. An increased endothelial surface area might
provide easier access to the bloodstream. A complemen-
tary effect of high vascularity is the more pronounced para-
crine interaction between endothelial cells and tumour
cells. Activated endothelial cells can indeed produce
tumour cell growth factors, for example IL-6 in the vertical
growth phase of melanoma [31], or matrix remodelling
enzymes that facilitate tumour cell motility and invasion, as
demonstrated in skin carcinogenesis models [32]. The sur-
vival and growth of tumour cells can also be influenced by
endocrine interactions with a primary tumour present. In
cervical, ovarian and colorectal cancer IL-6 is shed in the
blood by the tumour, creating a 2.5-fold arteriovenous
gradient [33]. In this study, patients with a Chalkley count
of 7 or more had concentrations of circulating IL-6 that
were about 2.5-fold higher than patients with a Chalkley
count of less than 7 (P = 0.018). This is in accord with the
Figure 4
Cytokeratin-19 relative gene expression (CK-19 RGE) and D-dimers Cytokeratin-19 relative gene expression (CK-19 RGE) and D-dimers. 
(a) Correlation analysis of CK-19 RGE and D-dimers. (b) Analysis of D-
dimers in relation to categorised CK-19 RGE.Available online http://breast-cancer-research.com/content/7/2/R210
R218
angiogenic potential of IL-6. In metastatic breast cancer,
high levels of circulating IL-6 predict a shortened survival
time [13].
Unlimited haemostasis is intimately linked to tumour growth
and angiogenesis, and tumours can therefore be regarded
as non-healing wounds [34]. Immunohistochemical analy-
ses with antibodies directed at fibrin demonstrated
abundant stromal fibrin depositions in inflammatory breast
cancer, a highly aggressive and highly angiogenic type of
breast cancer, and less or no fibrin in non-inflammatory
breast cancer [35]. A relation of high Chalkley counts and
the presence of fibrin in the tumour was also reported in
cutaneous breast cancer deposits [36]. In this study, levels
of D-dimers in plasma, as a reflection of active fibrin remod-
elling, were correlated with CK-19 RGE values (r = 0.23; P
= 0.08). Levels of D-dimers in patients with CK-19 RGE
values of 0.77 or more were 1.4-fold those in patients with
CK-19 RGE values of less than 0.77 (P = 0.09). Signifi-
cantly higher levels of plasma D-dimers have been found in
veins draining colorectal adenocarcinomas than in arteries
[33], suggesting that plasma D-dimer levels are a measure
of matrix remodelling in the tumour. Elevated levels of circu-
lating D-dimers have been correlated with enhanced pro-
gression kinetics and reduced overall survival in metastatic
breast cancer [12]. Taken together, these results strongly
suggest interactions between angiogenesis and haemosta-
sis to facilitate metastasis in breast cancer.
Conclusion
In conclusion, our data show that tumour vascularity, and
not lymph node status, independently predicts the pres-
ence of PCR-detected bone marrow micrometastases.
This is consistent with direct haematogenous spread from
the primary breast cancer without orderly progression from
local to nodal to distant disease.
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